We are live on ! Find out more

1,781 hedge funds and large institutions have $145B invested in Pfizer in 2014 Q1 according to their latest regulatory filings, with 117 funds opening new positions, 733 increasing their positions, 747 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 117 | Existing positions closed: 55

110% more call options, than puts

Call options by funds: $1.89B | Put options by funds: $900M

10% more funds holding in top 10

Funds holding in top 10: 250274 (+24)

3% more funds holding

Funds holding: 1,7371,781 (+44)

5% more capital invested

Capital invested by funds: $138B → $145B (+$6.46B)

0.72% more ownership

Funds ownership: 73.18%73.9% (+0.72%)

2% less repeat investments, than reductions

Existing positions increased: 733 | Existing positions reduced: 747

Holders
1,781
Holders Change
+44
Holders Change %
+2.53%
% of All Funds
51.41%
Holding in Top 10
274
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+9.6%
% of All Funds
7.91%
New
117
Increased
733
Reduced
747
Closed
55
Calls
$1.89B
Puts
$900M
Net Calls
+$990M
Net Calls Change
+$946M
Name Holding Trade Value Shares
Change
Change in
Stake
SG Americas Securities
201
SG Americas Securities
New York
$85.4M -$69.7M -2,337,341 -45%
PC
202
Polar Capital
United Kingdom
$84.9M +$23.1M +774,885 +39%
WCM
203
Winton Capital Management
United Kingdom
$84.6M +$21.5M +721,983 +35%
Stifel Financial
204
Stifel Financial
Missouri
$82.5M +$80.7M +2,706,912 New
MPI
205
Mairs & Power Inc
Minnesota
$82.3M -$277K -9,277 -0.3%
DekaBank Deutsche Girozentrale
206
DekaBank Deutsche Girozentrale
Germany
$80.5M +$4.14M +138,712 +6%
CCMH
207
Cornerstone Capital Management Holdings
New York
$80M -$4.1M -137,672 -5%
CBOA
208
Commonwealth Bank of Australia
Australia
$79.4M -$17.4M -583,728 -18%
TAM
209
Tocqueville Asset Management
New York
$79.3M -$2.73M -91,572 -3%
HFS
210
HL Financial Services
Kentucky
$78.7M +$221K +7,398 +0.3%
SIA
211
Sit Investment Associates
Minnesota
$77.9M -$1.73M -58,027 -2%
WCMNY
212
Westchester Capital Management (New York)
New York
$77.4M +$11.2M +374,381 +17%
AI
213
Analytic Investors
California
$75.8M -$29.3M -982,447 -28%
EAM
214
Eagle Asset Management
Florida
$75.6M +$6.94M +232,709 +10%
WBC
215
Westpac Banking Corp
Australia
$75.4M +$21.2M +709,460 +40%
Public Sector Pension Investment Board (PSP Investments)
216
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$75.1M -$4.66M -156,309 -6%
CB
217
Commerce Bank
Missouri
$74.4M +$802K +26,909 +1%
CEP
218
Chicago Equity Partners
Illinois
$72.4M +$5.47M +183,501 +8%
DL
219
Delta Lloyd
Netherlands
$72.3M +$51.1M +1,714,171 +260%
GF
220
Gabelli Funds
New York
$71.1M -$880K -29,512 -1%
GT
221
Glenmede Trust
Pennsylvania
$71M +$478K +16,029 +0.7%
JMPWA
222
JP Morgan Private Wealth Advisors
California
$70M +$6.09M +204,190 +10%
BFM
223
Boston Financial Management
Massachusetts
$69.4M +$2.51M +84,193 +4%
SCP
224
Seizert Capital Partners
Michigan
$69.4M -$4.23M -141,880 -6%
KBG
225
Kahn Brothers Group
New York
$67.9M +$6.7M +224,565 +11%

PFE Hedge Fund Activity: Q1 2014 in Review

1,781 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2014, worth a combined $145B — up 4.7% from $138B a quarter earlier.

Buyers outnumbered sellers: 117 funds opened new PFE positions and 55 closed out — a net gain of 62 holders — while 733 added to existing stakes and 747 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $301M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $630M.

  • 1,781 institutional investors held Pfizer (PFE) as of Q1 2014, up from 1,737 in Q4 2013.
  • Funds reported $145B of Pfizer stock for Q1 2014, up 4.7% quarter-over-quarter.
  • 117 funds opened new Pfizer positions in Q1 2014 and 55 closed out, a net change of +62 holders.
  • The largest Pfizer buyer in Q1 2014 was BlackRock Fund Advisors, an estimated $301M added.
  • The largest Pfizer seller in Q1 2014 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $630M sold.

Based on aggregated 13F filings for Q1 2014.